Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Ibrance

Ibrance®, palbociclib, is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with
• an aromatase inhibitor as initial endocrine based therapy in postmenopausal women e.g. Letrozole

or

• fulvestrant in women with disease progression following endocrine therapy

To Read More>>

To get a personal free assessment to our service please in fill in your details and we will get back to you shortly

Improve therapeutic outcomes, prolong life and quality of life are our main business. We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Close Menu